These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 28412066)

  • 41. Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab.
    Zhou Y; Jiang Y; Bai Y; Wen J; Chen L
    Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):31-6. PubMed ID: 25851862
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Time Course of Retinopathy of Prematurity Regression and Reactivation After Treatment with Ranibizumab or Laser in the RAINBOW Trial.
    Fleck BW; Reynolds JD; Zhu Q; Lepore D; Marlow N; Stahl A; Li J; Weisberger A; Fielder AR;
    Ophthalmol Retina; 2022 Jul; 6(7):628-637. PubMed ID: 35202890
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FACTORS ASSOCIATED WITH REACTIVATION AFTER INTRAVITREAL BEVACIZUMAB OR RANIBIZUMAB THERAPY IN INFANTS WITH RETINOPATHY OF PREMATURITY.
    Iwahashi C; Utamura S; Kuniyoshi K; Sugioka K; Konishi Y; Wada N; Kusaka S
    Retina; 2021 Nov; 41(11):2261-2268. PubMed ID: 33958533
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity.
    Castellanos MA; Schwartz S; García-Aguirre G; Quiroz-Mercado H
    Br J Ophthalmol; 2013 Jul; 97(7):816-9. PubMed ID: 23221964
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of Bevacizumab and Ranibizumab in the Treatment of Type 1 Retinopathy of Prematurity Affecting Zone 1.
    Kimyon S; Mete A
    Ophthalmologica; 2018; 240(2):99-105. PubMed ID: 29920490
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of the Efficacy Between Intravitreal Aflibercept and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity.
    Ekinci DY; Çelik K
    J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):54-60. PubMed ID: 31972042
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
    Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
    Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intravitreal ranibizumab versus laser photocoagulation for retinopathy of prematurity: efficacy, anatomical outcomes and safety.
    Kang HG; Choi EY; Byeon SH; Kim SS; Koh HJ; Lee SC; Kim M
    Br J Ophthalmol; 2019 Sep; 103(9):1332-1336. PubMed ID: 30514709
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reactivation of retinopathy of prematurity after bevacizumab injection.
    Hu J; Blair MP; Shapiro MJ; Lichtenstein SJ; Galasso JM; Kapur R
    Arch Ophthalmol; 2012 Aug; 130(8):1000-6. PubMed ID: 22491394
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison in Retreatments between Bevacizumab and Ranibizumab Intravitreal Injections for Retinopathy of Prematurity: A Multicenter Study.
    Patel NA; Acaba-Berrocal LA; Hoyek S; Fan KC; Martinez-Castellanos MA; Baumal CR; Harper CA; Berrocal AM;
    Ophthalmology; 2023 Apr; 130(4):373-378. PubMed ID: 36396121
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Results of intravitreal ranibizumab treatment for retinopathy of prematurity in infants.
    Sukgen EA; Koçluk Y
    Cutan Ocul Toxicol; 2017 Dec; 36(4):356-361. PubMed ID: 28277877
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chronic Vascular Arrest as a Predictor of Bevacizumab Treatment Failure in Retinopathy of Prematurity.
    Toy BC; Schachar IH; Tan GS; Moshfeghi DM
    Ophthalmology; 2016 Oct; 123(10):2166-75. PubMed ID: 27506484
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Refractive error outcomes after intravitreal ranibizumab for retinopathy of prematurity.
    Meng Q; Cheng Y; Wu X; Zhao D; Zhao M; Liang J
    Clin Exp Optom; 2020 Jul; 103(4):495-500. PubMed ID: 31802528
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity.
    Gangwe AB; Agrawal D; Gangrade AK; Parchand SM; Agrawal D; Azad RV
    Indian J Ophthalmol; 2021 Aug; 69(8):2171-2176. PubMed ID: 34304203
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of post-treatment recurrence between ranibizumab injection and laser photocoagulation for type 1 retinopathy of prematurity.
    Cao JK; Han T; Tang HY; Zhang S; Wang ZH; Feng ZC; Li QP
    BMC Ophthalmol; 2023 Apr; 23(1):137. PubMed ID: 37016343
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Appropriate dose of intravitreal ranibizumab for ROP: a retrospective study.
    Chen Y; Wang S; Chen S; Chen X; Han L; Zhong Q; Zhang K
    BMC Ophthalmol; 2022 Jun; 22(1):271. PubMed ID: 35729540
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The clinical study on intravitreous injection of ranibizumab for aggressive posterior retinopathy of prematurity].
    Tian R; Zhang G; Tang S; Guo J; Tan W
    Zhonghua Yan Ke Za Zhi; 2015 Nov; 51(11):822-5. PubMed ID: 26850583
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Conserved regression patterns of retinopathy of prematurity after intravitreal ranibizumab: A class effect.
    Ji MH; Moshfeghi DM; Shields RA; Bodnar Z; Ludwig CA; Callaway NF; Orazi L; Amorelli GM; Lepore D
    Eur J Ophthalmol; 2021 Jul; 31(4):2135-2140. PubMed ID: 32722932
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Dosing Study of Bevacizumab for Retinopathy of Prematurity: Late Recurrences and Additional Treatments.
    Wallace DK; Dean TW; Hartnett ME; Kong L; Smith LE; Hubbard GB; McGregor ML; Jordan CO; Mantagos IS; Bell EF; Kraker RT;
    Ophthalmology; 2018 Dec; 125(12):1961-1966. PubMed ID: 29887334
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The vascularization process after intravitreal ranibizumab injections for aggressive posterior retinopathy of prematurity.
    Sukgen EA; Koçluk Y
    Arq Bras Oftalmol; 2017; 80(1):30-34. PubMed ID: 28380099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.